Insider Buying: HCW Biologics (NASDAQ:HCWB) SVP Acquires 7,736 Shares of Stock

HCW Biologics Inc. (NASDAQ:HCWB) SVP Lee Flowers bought 7,736 shares of the firm’s stock in a transaction dated Wednesday, July 29th. The stock was purchased at an average cost of $2.58 per share, for a total transaction of $19,958.88. Following the transaction, the senior vice president directly owned 8,691 shares of the company’s stock, valued at $22,422.78. The trade was a 810.05% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

HCW Biologics Stock Performance

NASDAQ:HCWB traded up $0.05 during mid-day trading on Friday, hitting $3.20. 61,185 shares of the stock were exchanged, compared to its average volume of 1,508,655. The stock has a market capitalization of $5.11 million, a price-to-earnings ratio of -0.06 and a beta of 2.29. The firm’s 50-day simple moving average is $6.78 and its 200 day simple moving average is $5.21. HCW Biologics Inc. has a fifty-two week low of $1.50 and a fifty-two week high of $44.10.

HCW Biologics (NASDAQ:HCWB) last released its quarterly earnings results on Thursday, May 14th. The company reported $0.37 earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.64) by $3.01. HCW Biologics had a negative return on equity of 486.87% and a negative net margin of 34.73%.The business had revenue of $6.54 million during the quarter, compared to the consensus estimate of $6.54 million.

Analysts Set New Price Targets

A number of analysts have issued reports on the stock. Wall Street Zen raised shares of HCW Biologics to a “hold” rating in a report on Saturday, May 23rd. Maxim Group raised their target price on shares of HCW Biologics from $12.00 to $30.00 and gave the stock a “buy” rating in a report on Thursday, May 28th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of HCW Biologics in a research report on Friday, July 17th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $30.00.

Institutional Trading of HCW Biologics

An institutional investor recently bought a new stake in HCW Biologics stock. Armistice Capital LLC purchased a new position in HCW Biologics Inc. (NASDAQ:HCWB) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned 9.15% of HCW Biologics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 2.96% of the company’s stock.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.